
    
      Sub-study: Does anacetrapib as a CETP inhibitor lead to mobilization of stem cells and
      enhance myocardial function via neoangiogenesis and tissue regeneration?

      Following the main on-treatment part of the study, there will be a further period of at least
      2 years during which participants will be followed-up by telephone, off treatment.
    
  